Patents Examined by Savitha Rao
  • Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
    Patent number: 9024042
    Abstract: Compositions and methods for treating glaucoma are provided. In particular hydrophilic ester prodrugs and their use to reduce central corneal thickening is provided.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: May 5, 2015
    Assignee: Allergan, Inc.
    Inventors: Wha-Bin Im, Robert M. Burk
  • Use of electrophilic compounds for inducing platelet production or maintaining platelet function
    Patent number: 9012439
    Abstract: The present invention is directed to a method of inducing platelet production that includes contacting a megakaryocyte with an electrophilic compound under conditions effective to induce platelet production by the contacting megakaryocyte. Methods of treating a patient for low platelet levels, increasing the circulating half-life of platelets, and improving the quality (activity) of platelets are also disclosed herein, which involve administering the electrophilic compound to a patient an effective amount to achieve the desired effect. Pharmaceutical compositions and therapeutic systems are also disclosed for carrying out these therapeutic treatments.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: April 21, 2015
    Assignee: University of Rochester
    Inventors: Richard P. Phipps, Jamie O'Brien
  • Method of treating neuropathic pain
    Patent number: 9012477
    Abstract: A method for treating subjects experiencing neuropathic pain is provided. The method involves the application of a solid-forming local anesthetic formulation to a skin surface of the subject experiencing the neuropathic pain and then maintaining the formulation on the skin surface for a period of time sufficient to allow itself to transdermally deliver the local anesthetic to the subject thereby providing relief from the neuropathic pain within about 45 minutes.
    Type: Grant
    Filed: January 5, 2010
    Date of Patent: April 21, 2015
    Assignee: Nuvo Research Inc.
    Inventors: Jie Zhang, Robert Lippert
  • Composition comprising dihomo-?-linolenic acid (DGLA) as active ingredient
    Patent number: 9006287
    Abstract: The present invention provides a composition, such as a food and pharmaceutical agent, which comprises dihomo-?-linolenic acid, and which has the effect of preventing or treating skin diseases; a composition such as a food and pharmaceutical agent which comprises dihomo-?-linolenic acid and which has the effect of preventing or treating skin diseases; and a composition which comprises dihomo-?-linolenic acid and which has the effect of preventing or treating diseases related to increased mast cell count.
    Type: Grant
    Filed: February 10, 2006
    Date of Patent: April 14, 2015
    Assignee: Suntory Holdings Limited
    Inventors: Norifumi Tateishi, Hiroshi Kawashima
  • Pharmaceutical compositions and method for treating inflammation in cattle and other animals
    Patent number: 9006272
    Abstract: Novel transdermal preparations combining a non-steroidal anti-inflammatory drug (NSAID) such as flunixin, are disclosed. Methods for using and administering such preparation in the treatment of inflammatory conditions in bovines, including bovine respiratory disease, are also disclosed.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: April 14, 2015
    Assignee: Intervet Inc.
    Inventors: Cheyney Meadows, Keith A. Freehauf, Robert D. Simmons, Allan J. Weingarten
  • Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
    Patent number: 8999975
    Abstract: The present invention is directed to compounds of Formula I: wherein R1, R2 and n are described herein. These compounds and their pharmaceutically acceptable salts thereof are inhibitors of Cathepsin C.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: April 7, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Marc Grundl, Thorsten Oost, Alexander Pautsch, Stefan Peters, Doris Riether, Wolfgang Wienen
  • Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, bcl-2 and caspase-3
    Patent number: 9000027
    Abstract: The invention describes methods that are useful for treating cancer by administering a Chk1 inhibitor which can induce apoptosis in p53-defective cells when combined with a chemotherapy and/or radiotherapy. Methods for screening candidates for a Chk1 inhibitor-based cancer treatment regimen are also described.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: April 7, 2015
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: A. Thomas Look, Samuel Sidi
  • Ire1alpha endonuclease specific inhibitor with cytotoxic activity
    Patent number: 8993617
    Abstract: The present invention directed to a method of treating multiple myeloma with the following compound: or a pharmaceutically acceptable salt thereof. The compound is a novel small molecule inhibitor of Ire1.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: March 31, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Albert C. Koong, Ioanna Papandreou
  • Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
    Patent number: 8993599
    Abstract: In one general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a material that enhances the shelf-life of the pharmaceutical composition and one or more antacid are described. In another general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a taste-masking material and one or more antacid are described.
    Type: Grant
    Filed: January 24, 2006
    Date of Patent: March 31, 2015
    Assignee: Santarus, Inc.
    Inventors: Warren Hall, Kay Olmstead, Laura Weston
  • Methods for treating viral disorders
    Patent number: 8993581
    Abstract: Disclosed are methods of treating viral disorders via the administration of an inducing agent and an anti-viral agent. In one embodiment, the inducing agent and the anti-viral agent are administered for about five days, and the anti-viral agent is subsequently administered without the inducing agent for an additional period of about sixteen days for a total cycle of about 21 days.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: March 31, 2015
    Assignee: Trustees of Boston University
    Inventors: Susan Perrine, Douglas Faller
  • Inhibitors of arachidonic acid formation
    Patent number: 8987325
    Abstract: The invention relates to a novel class of inhibitors of arachidonic acid formation that can be useful for treating inflammatory conditions. Specifically, the invention relates to derivatives of sesamol that confer lower toxicity and increased circulatory lifetimes than pure sesamol.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: March 24, 2015
    Inventor: Barry D. Sears
  • Benzothiophene compound
    Patent number: 8981119
    Abstract: The present invention is directed to compounds of Formula I: wherein R1, R2, R3, R4, R5, X and n are described herein. These compounds and their pharmaceutically acceptable salts thereof are useful as IK1 channel activators.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: March 17, 2015
    Assignee: Astellas Pharma Inc.
    Inventors: Tsukasa Ishihara, Kazuhiro Ikegai, Ikumi Kuriwaki, Hiroyuki Hisamichi, Nobuaki Takeshita, Ryuichi Takezawa
  • Lipid compositions for the treatment of gastro-intestinal disorders and the promotion of intestinal development and maturation
    Patent number: 8980949
    Abstract: The present invention provides a use of a lipid composition for the preparation of a nutritional, pharmaceutical or nutraceutical composition or a functional food, for the prevention and treatment of gastrointestinal diseases and disorders, and for promoting intestinal development, maturation, adaptation and differentiation.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: March 17, 2015
    Assignee: Enzymotec Ltd.
    Inventors: Fabiana Bar-Yosef, Gai Ben Dror, Tzafra Cohen, Yael Lifshitz
  • Viral inhibitor compositions for in vivo therapeutic use comprising a combination of (?)-carvone, geraniol and a further essential oil component
    Patent number: 8980945
    Abstract: The present invention concerns an antiviral composition comprising the following components: R-(?)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (also called (?) carvone) and S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (also called (+) carvone) and (2E)-3,7-dimethylocta-2,6-dien-1-ol (also called trans-geraniol) in combination with at least one more component chosen among essential oils components for use in treatment and prevention of diseases caused by DNA enveloped viruses, DNA non-enveloped viruses, RNA enveloped viruses and RNA non-enveloped viruses.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: March 17, 2015
    Assignee: Cessa Alliance
    Inventor: Christine Coppens
  • Oral forms of a phosphonic acid derivative
    Patent number: 8980868
    Abstract: Novel solution complexes of zoledronic acid are described which give rise to improved properties of zoledronic acid. The invention includes aqueous solution and molecular complexes of zoledronic acid with and optical isomers of asparagine, histidine, arginine and proline as well as pharmaceutical complexes containing them and methods of treatment using them.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: March 17, 2015
    Assignee: Thar Pharmaceuticals, Inc.
    Inventors: Mazen Hanna, Ning Shan, Miranda Cheney, David Weyna
  • Methods and compositions for treating infections comprising a local anesthetic
    Patent number: 8980317
    Abstract: The present invention is directed to a drug depot useful for reducing, preventing or treating an infection in a patient in need of such treatment. The drug depot includes a polymer and a therapeutically effective amount of a local anesthetic or pharmaceutically acceptable salt thereof. The drug depot is administered at a site to reduce, prevent or treat an infection. The drug depot is capable of releasing (i) a bolus dose of the local anesthetic or pharmaceutically acceptable salt thereof at the site and (ii) a sustained release dose of an effective amount of the local anesthetic or pharmaceutically acceptable salt thereof over a period of at least 4 days at the site.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: March 17, 2015
    Assignee: Warsaw Orthopedic, Inc.
    Inventor: Vanja Margareta King
  • Intrathecal baclofen pharmaceutical dosage forms with fewer degradation products
    Patent number: 8969414
    Abstract: The present invention relates generally to a sterile, particulate-free, stable intrathecal baclofen solution with less than 0.5% 4-(4-chlorophenyl)-2-pyrrolidone, a degradation product. These solutions are stable under a variety of storage conditions and for extended periods of time. Also disclosed are methods for preparing such compositions.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: March 3, 2015
    Assignee: Mallinckrodt LLC
    Inventors: John J. Foster, Angela S. Strantz
  • Compositions and methods for weight loss in at risk patient populations
    Patent number: 8969371
    Abstract: The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: March 3, 2015
    Assignee: Orexigen Therapeutics, Inc.
    Inventors: Preston Klassen, Kristin Taylor
  • 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
    Patent number: 8969355
    Abstract: This disclosure relates to a method of treating a disease selected from the group consisting of affective disorders, depression, major depressive disorder, anxiety, general anxiety disorder, social anxiety disorder, obsessive compulsive disorder, panic disorder, and panic attacks. The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to a patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: March 3, 2015
    Assignee: H. Lundbeck A/S
    Inventors: Benny Bang-Andersen, Andre Faldt, Rene Holm, Heidi Lopez de Diego
  • Causal therapy of diseases or conditions associated with CNS or PNS demyelination
    Patent number: 8962676
    Abstract: The present invention is directed to the treatment of demyelination as an underlying cause of the disease of multiple sclerosis (MS) in a mammal, the method comprising promoting remyelination of myelination of axonal cells by administering to the mammal a 2-oxopyrrolidine compound having a general formula I: wherein R?R??H, and R??CH2CONH-(2,6CH3)C6H3 or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: February 24, 2015
    Assignee: University College Dublin, National University of Ireland, Dublin
    Inventors: Mark Pickering, Keith Murphy